Dec 18 $80 / $90 Bull Call Spread
Buy 1x $80C · Sell 1x $90C · 31d
Updated Nov 21, 2026 5:51 PM ET · Prev Close $80.19
DexCom, Inc. (DXCM) is trading within a tight intraday band at $79.32 (-1.08%, 0.92x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DXCM is outperforming the S&P 500 by +2.56%. 14-day RSI stands at 43.0, keeping momentum in a bearish regime.
Boost ROI with AI analytics, remote monitoring, cloud-based real-world evidence, precision biomarker tracking and wearable injectors that enable at-home biologic delivery.Dublin, Nov. 19, 2026 Globe Newswire -- Clinical-
Price ($79.32) trades relative to 20-day SMA ($81.49) and 50-day SMA ($83.94).
Compare $8,161 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 39.6% ATM IV.
Buy 1x $80C · Sell 1x $90C · 31d
Sell 1x $75P · Buy 1x $70P · 31d
Buy 1x $85P · Sell 1x $75P · 31d
Boost ROI with AI analytics, remote monitoring, cloud-based real-world evidence, precision biomarker tracking and wearable injectors that enable at-home biologic delivery.Dublin, Nov. 19, 2026 Globe Newswire -- Clinical-
Athenry, Ireland, November 19, 2026--DexCom, Inc. Nasdaq DXCM , a global leader in continuous glucose monitoring, today officially opened its state-of-the-art manufacturing facility in Athenry, County Galway, marking a m
DexCom Nasdaq Dxcm expects a record number of new patients in 2026 and is preparing for a potential expansion of Medicare coverage for continuous glucose monitoring, executives said during a discussion hosted by Jefferie
Are analysts predicting CGM-maker DexCom to rise or fall?
Monitor volume expansion above 1.5x RVOL around $81.49 (20-day SMA resistance) for directional breakout confirmation.
DexCom expects a record number of new patients in 2026 due to potential Medicare coverage expansion for continuous glucose monitoring, with the decision from the Centers for Medicare and Medicaid Services (CMS) anticipated before year-end.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
Receive an email alert when DXCM triggers an unusual volume breakout, options sweep, or rating shift.
DexCom, Inc. (DXCM) is trading within a tight intraday band at $79.32 (-1.08%, 0.92x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, DXCM is outperforming the S&P 500 by +2.56%. 14-day RSI stands at 43.0, keeping momentum in a bearish regime.
Today's session carries a 64% catalyst conviction score on 0.92x relative volume (moderate participation). Our multi-factor model currently rates DXCM as HOLD. Review full valuation, quality, and timing signals on the DXCM Buy or Sell Decision Brief →
At $79.32, DXCM's modeled 1-to-3 session range is $76.74 – $81.90, with a key inflection level at $81.49 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the DXCM Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
RSI at 43.0 reflects soft below-midline momentum. DXCM trades at $79.32 relative to its 20-day SMA ($81.49) and 50-day SMA ($83.94), reflecting a bearish moving-average structure.
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.